Vitrolife Q3’20: First comments – Recovery

Research Note

2020-11-06

08:37

Redeyes first impression of the third-quarter report. Sales amounted to SEK 320m, a decrease of 15% in SEK. Thus, 8 % higher than our expected SEK 298m. The Covid-19 continues to affect sales but not as harsh as in the second quarter. EBIT was also considerably higher than we and the street expected at SEK 112m vs. our expected SEK 79m. (Estimated consensus SEK 81m). We will revise our estimates uppwards after a better than expected report.

MH

Mats Hyttinge

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.